Predictors of higher EULAR response at 3-month follow-up to MTX monotherapy*
| All patients | ||
|---|---|---|
| Univariate analysis OR (95% CI) | Multivariate analysis OR (95% CI)† | |
| Number | 322 | 322 |
| Demographic | ||
| Female | 0.54 (0.35 to 0.86) | 0.50 (0.31 to 0.81) |
| Age (per 10 years increase) | 1.27 (1.10 to 1.47) | 1.30 (1.11 to 1.51) |
| Symptom duration (per month) | 0.95 (0.90 to 1.01) | 0.93 (0.88 to 0.99) |
| Current smoking‡ | 0.51 (0.30 to 0.87) | 0.35 (0.20 to 0.63) |
| Past smoking‡ | 0.92 (0.57 to 1.49) | 0.68 (0.41 to 1.12) |
| Baseline disease parameters§ | ||
| Rheumatoid factor positive | 1.01 (0.66 to 1.56) | 1.28 (0.81 to 2.00) |
| Anti-CCP antibody positive | 1.06 (0.70 to 1.62) | 1.25 (0.80 to 1.96) |
| DAS28 (per unit increase) | 0.70 (0.57 to 0.85) | 0.64 (0.52 to 0.80) |
| HAQ (per unit increase) | 0.60 (0.44 to 0.83) | 0.56 (0.40 to 0.80) |
| Concurrent therapy | ||
| Prednisolone | 1.92 (1.02 to 3.64) | 2.84 (1.43 to 5.63) |
| NSAIDs | 1.06 (0.70 to 1.62) | 1.31 (0.84 to 2.06) |
↵* Association between each parameter and the chance of reaching a higher EULAR response category after 3 months (no, moderate good), calculated by ordinal logistic regression.
↵† Adjusted for age, gender, symptom duration, current smoking, past smoking, anti-CCP status, baseline HAQ, concurrent prednisolone and NSAID use.
↵‡ In univariate smoking analyses, current and past smokers are separately compared to never smokers, while both are kept in the multivariate model.
↵§ As high collinearity was observed for anti-CCP and RF status, and also HAQ score and DAS28, only anti-CCP status and HAQ were kept in the model, and excluded when RF status and DAS28, respectively, were analysed.
anti-CCP, anti-cyclic citrullinated peptide antibody; CDAI, Clinical Disease Activity Index; DAS28, 28-joint Disease Activity Score; HAQ, Health Assessment Questionnaire; IQR, interquartile range; NSAIDs, non-steroidal anti-inflammatory drugs; RF, rheumatoid factor; SDAI Simple Disease Activity Index.